Integrating opportunistic EAT assessment into lung cancer screening could enhance risk stratification with targeted interventions, such as anti-inflammatory therapies (e.g. colchicine and IL-6 inhibitors) and metabolic treatments (e.g. GLP-1 receptor agonists and SGLT-2 inhibitors),37–39 which may be of greater benefit to women than to men. The gene discussed is SLC5A2; the disease is lung carcinoma.